Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.

Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.

Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein n1, n2, n3, n4, G1, Q1, Z, R1, R2, R3, R4a, R4b, R5a, and R5b are defined herein, inhibit the cytochrome P450RAI enzyme and are useful for the treatment and/or prevention of various diseases and conditions which respond to treatment by retinoids and by naturally occurring retinoic acid.

Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.

Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.

Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein Q1 and R1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of various diseases and conditions that respond to treatment by inhibition of tyrosine kinases.

Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.

Abstract: A method for processing data. Meta-data descriptors (15, 18) are defined to describe the data either by the user (17) or automatically using a meta-data connector (16). A meta-data descriptor describes the structure of data including field names (1, 4). A meta-data connector describes how to access the data. Different types of meta-data connectors (10, 11, 12) exist for different types of data such as JDBC and XML. An interactive user application (23) is utilised to facilitate the definition of a process. A process consists of certain operations (7) in relation to meta-data descriptors (2, 5) such as transformation of data from one field name to another. A component (8, 26) is provided to process data in accordance with the defined process. A computer system and software for implementing the method is also disclosed.

Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein Q1 and R1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of various diseases and conditions that respond to treatment by inhibition of tyrosine kinases.

Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein n1, n2, n3, n4, G1, Q1, Z, R1, R2, R3, R4a, R4b, R5a, and R5b are defined herein, inhibit the cytochrome P450RAI enzyme and are useful for the treatment and/or prevention of various diseases and conditions which respond to treatment by retinoids and by naturally occurring retinoic acid.

Abstract: A golf club head having a matrix layer composed of an interconnected reinforcement structure and a polymer material is disclosed herein. The matrix layer provides the golf club head with a greater coefficient of restitution during impact with a golf ball. The matrix layer is preferably disposed within a recess in the front wall of the body of the golf club head. The interconnected reinforcement structure is preferably composed of interconnected hexagonal cells.

Abstract: A condom is provided with magnetic material disposed in a flexible polymeric material condom at the open end of the condom. The magnetic material may be a magnetized ferrometallic split ring in the open end rib or magnetized ferrometallic particulates embedded in the polymeric material adjacent the condom open end. A permanent or rare earth magnet is fixedly disposed in the condom package to provide magnetizing force to the ferrometallic material in of the rolled condom. Alternatively, a permanent or rare earth magnet in a split ring construction may be embedded in the rib formed at the condom open end.

Abstract: A condom is provided with magnetic material disposed in a flexible polymeric material condom at the open end of the condom. The magnetic material may be a magnetized ferrometallic split ring in the open end rib or magnetized ferrometallic particulates embedded in the polymeric material adjacent the condom open end. A permanent or rare earth magnet is fixedly disposed in the condom package to provide magnetizing force to the ferrometallic material in of the rolled condom. Alternatively, a permanent or rare earth magnet in a split ring construction may be embedded in the rib formed at the condom open end.

Abstract: A condom is provided with magnetic material disposed in a flexible polymeric material condom at the open end of the condom. The magnetic material may be a magnetized ferrometallic split ring in the open end rib or magnetized ferrometallic particulates embedded in the polymeric material adjacent the condom open end. A permanent or rare earth magnet is fixedly disposed in the condom package to provide magnetizing force to the ferrometallic material in of the rolled condom. Alternatively, a permanent or rare earth magnet in a split ring construction may be embedded in the rib formed at the condom open end.

Abstract: A condom is provided with magnetic material disposed in a flexible polymeric material condom at the open end of the condom. The magnetic material may be a magnetized ferrometallic split ring in the open end rib or magnetized ferrometallic particulates embedded in the polymeric material adjacent the condom open end. A permanent or rare earth magnet is fixedly disposed in the condom package to provide magnetizing force to the ferrometallic material in of the rolled condom. Alternatively, a permanent or rare earth magnet in a split ring construction may be embedded in the rib formed at the condom open end.

Abstract: A condom is provided with magnetic material disposed in a flexible polymeric material condom at the open end of the condom. The magnetic material may be a magnetized ferrometallic split ring in the open end rib or magnetized ferrometallic particulates embedded in the polymeric material adjacent the condom open end. A permanent or rare earth magnet is fixedly disposed in the condom package to provide magnetizing force to the ferrometallic material in of the rolled condom. Alternatively, a permanent or rare earth magnet in a split ring construction may be embedded in the rib formed at the condom open end.

Abstract: A condom is provided with magnetic material disposed in a flexible polymeric material condom at the open end of the condom. The magnetic material may be a magnetized ferrometallic split ring in the open end rib or magnetized ferrometallic particulates embedded in the polymeric material adjacent the condom open end. A permanent or rare earth magnet is fixedly disposed in the condom package to provide magnetizing force to the ferrometallic material in of the rolled condom. Alternatively, a permanent or rare earth magnet in a split ring construction may be embedded in the rib formed at the condom open end.